Last updated: May 28, 2026

Application No. 17/920,583

H4 ANTAGONIST COMPOUNDS

Final Rejection

Filed

Oct 21, 2022

Priority

Apr 22, 2020 — GB 2005858.2 +1 more

Examiner

MCDOWELL, BRIAN E

Art Unit

1624

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Nxera Pharma UK Limited

OA Round

2 (Final)

Interview Optional

— +30.6% interview lift. Examiner has a relatively high allowance rate (74%); +30.6% interview lift. A written response may suffice.

Based on 1111 resolved cases, 2023–2026

Examiner Intelligence

MCDOWELL, BRIAN E View full profile →

Grants 74% — above average

Career Allowance Rate

825 granted / 1111 resolved

+14.3% vs TC avg

Strong +31% interview lift

Without

With

+30.6%

Interview Lift

resolved cases with interview

Typical timeline

2y 2m

Avg Prosecution

53 currently pending

Career history

1169

Total Applications

across all art units

Statute-Specific Performance

§101

0.3%

-39.7% vs TC avg

§103

23.5%

-16.5% vs TC avg

§102

19.1%

-20.9% vs TC avg

§112

51.1%

+11.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1111 resolved cases

Prosecution Timeline

Oct 21, 2022

Application Filed

Sep 05, 2025

Non-Final Rejection mailed

Dec 05, 2025

Response Filed

Feb 25, 2026

Final Rejection mailed

May 26, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

18/590,749

Patent 12636371

Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System

2y 2m to grant Granted May 26, 2026

18/196,601

Patent 12617782

PYRIDAZINONES AS PARP7 INHIBITORS

2y 11m to grant Granted May 05, 2026

19/223,498

Patent 12617774

SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF

11m to grant Granted May 05, 2026

17/575,898

Patent 12612381

CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE

4y 3m to grant Granted Apr 28, 2026

17/801,551

Patent 12606556

TYK-2 INHIBITOR

3y 8m to grant Granted Apr 21, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

74%

Grant Probability

99%

With Interview (+30.6%)

2y 2m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1111 resolved cases by this examiner. Grant probability derived from career allowance rate.